Rinvask Indications/Uses

Drug therapy should be one component of a comprehensive intervention strategy for patients requiring modification of their lipid profile. Pitavastatin is used as an adjunct to a diet restricted in saturated fat and cholesterol when the response to diet and other non-pharmacological measures is inadequate.
Primary Hyperlipidemia and Mixed Dyslipidemia: Pitavastatin is indicated as adjunctive therapy to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.
Heterozygous Familial Hypercholesterolemia (HeFH): For pediatric patients aged 8 years and older with a history of heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.
Limitations of Use: Doses of Pitavastatin greater than 4 mg once daily may increase the risk of severe myopathy. The use of Pitavastatin should not exceed 4 mg per day. The effect of Pitavastatin on cardiovascular morbidity and mortality has not been established. Pitavastatin has not been studied in patients with Fredrickson Type I, III, and V dyslipidemia.